• News

    Recent news on Salspera

      FDA GRANTS FAST TRACK DESIGNATION TO SALSPERA'S SALTIKVA, AN INNOVATIVE IMMUNOTHERAPEUTIC APPROACH TO TREAT METASTATIC PANCREATIC CANCER
    June 1, 2022
    Salspera today announced the U.S. Food and Drug Administration (FDA) granted Fast Track...
      FDA GRANTS ORPHAN DRUG DESIGNATION (ODD) TO SALSPERA'S SALTIKVA, AN INNOVATIVE IMMUNOTHERAPEUTIC APPROACH TO TREAT METASTATIC PANCREATIC CANCER
    May 23, 2022
    Salspera today announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug...
    Salspera Announces Positive Topline Data in Phase 2 Trial of Saltikva in Metastatic Pancreatic Cancer
    September 27, 2021
    Oakdale, MN, September 27th, 2021 – Salspera, LLC, a clinical stage biotechnology developing...
    More Posts
    All Posts
    ×
    Cookie Use
    We use cookies to ensure a smooth browsing experience. By continuing we assume you accept the use of cookies.
    Learn More